[1]张禄锴,马剑雄,赵杰,等.唑来膦酸抑制RAW264.7细胞系分化的最佳浓度体外实验[J].中华老年骨科与康复电子杂志,2018,(01):4-8.[doi:10.3877/cma.j.issn.2096-0263.2018.01.002]
　Zhang Lukai,Ma Jianxiong,Zhao Jie,et al.Effects and optimum concentration of zoledronate on RAW264.7[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2018,(01):4-8.[doi:10.3877/cma.j.issn.2096-0263.2018.01.002]
点击复制

唑来膦酸抑制RAW264.7细胞系分化的最佳浓度体外实验()
分享到：

中华老年骨科与康复电子杂志[ISSN:1674-3911/CN:11-9292/R]

卷:
期数:
2018年01期
页码:
4-8
栏目:
骨质疏松
出版日期:
2018-01-31

文章信息/Info

Title:
Effects and optimum concentration of zoledronate on RAW264.7
作者:
张禄锴1; 2; 马剑雄1; 赵杰1; 匡明杰1; 卢斌1; 王颖1; 孙磊1; 马信龙1; 3
300211 天津市天津医院骨科研究所1；300193 天津中医药大学研究生院2；300142 天津市天津医院3
Author(s):
Zhang Lukai 1; 2;  Ma Jianxiong1;  Zhao Jie1;  Kuang Mingjie1;  Lu Bin1;  Wang Ying1;  Sun Lei 1;  Ma Xinlong1.
1Orthopedics institute of Tianjin Hospital, Tianjin 300211, China; 2Graduate school of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China; 3Tianjin Hospital, Tianjin 300142, China
关键词:
唑来膦酸;  破骨细胞;  细胞分化;  细胞毒性;  RAW264.7
Keywords:
Zoledronic acid;  Osteoclast;  Cell differentiation;  Cytotoxicity;  RAW264.7
DOI:
10.3877/cma.j.issn.2096-0263.2018.01.002
文献标志码:
A
摘要:
目的 观察唑来膦酸盐对RAW264.7细胞系毒性作用的浓度范围和抑制RAW264.7分化为破骨细胞的最佳实验浓度。方法 以小鼠前破骨细胞系RAW264.7为研究对象，应用MTT法检测唑来膦酸盐对小鼠前破骨细胞系RAW264.7的毒性作用范围。使用TARP染色法观察不同浓度的唑来膦酸盐作用下破骨细胞的生成数目。结果 体外培养24 h后，酶联免疫反应吸光度结果显示，10-3 mol/L（0.511±0.920），10-4 mol/L（0.615±0.577）唑来膦酸对小鼠前破骨细胞系RAW264.7增殖有毒性作用，与空白对照组（0.789±0.061）相比，差异有统计学意义（F=5.880，P＜0.01）。TRAP染色破骨细胞计数结果显示：10-5 mol/L（8.333±0.817）、10-6 mol/L（10.400±1.817）、10-7 mol/L（11.250±2.750）及10-8 mol/L（11.143±1.864）唑来膦酸盐实验组破骨细胞数与空白对照组破骨细胞数（13.833±2.483）相比，差异具有统计学意义（F=27.972，P＜0.05），且呈浓度依赖性，当唑来膦酸盐浓度为10-5 mol/L时，抑制效果最明显（P＜0.01）。结论 唑来膦酸盐抑制RAW264.7细胞系分化为破骨细胞的最佳体外实验浓度为10-5 mol/L。
Abstract:
Objective To further observe the concentration range of zoledronate on RAW264.7 cell toxic effect and confirm the optimum concentration in inhibition of RAW264.7 differentiation of osteoclast. Methods Mouse leukemia macro phage RAW264.7 was cultured as research object. RAW264.7 osteoclast toxic effect of zoledronate was detected by MTT method. Inhibition of osteoclast differentiation by different concentration of zoledronate were detected by tartrate-resistant acid phosphatase staining method. Results After 24 h vitro culture, Enzyme-linked immunosorbent assay absorbance indicated that 10-3 mol/L (0.511±0.920), 10-4 mol/L (0.615±0.577) concentrations of zoledronate had significantly toxic effects on cells compared with the blank control group (0.789±0.061)(F=5.880, P<0.01). TRAP staining osteoclast count indicated that 10-5 mol/L (8.333±0.817), 10-6 mol/L (10.400±1.817), 10-7 mol/L (11.250±2.750) and 10-8 mol/L (11.143±1.864) concentrations of zoledronate all significantly inhibited RAW264.7 differentiation compared with the blank control group (F=27.972, P<0.05), showing concentration dependence, 10-5 mol/L zoledronate had the highest inhabitation effect (P<0.01). Conclusion Zoledronate can effectively inhibit RAW264.7 differentiation, and the optimum concentration in vitro is 10-5 mol/L.

参考文献/References:

1 Wallace IJ, Rubin CT, Lieberman DE. Osteoporosis [J]. Evol Med Public Health, 2015, (1): 343.
2 张智海, 张智若, 刘忠厚, 等. 中国大陆地区以-2.0SD为诊断标准的骨质疏松症发病率回顾性研究 [J]. 中国骨质疏松杂志, 2016, 22(1): 1-8.
3 Iba K, Yamashita T. Osteoclast-Mediated Pain in Osteoporosis [M]. Springer Japan, 2016: 23-34.
4 王想福, 孙凤岐, 叶丙霖, 等. 破骨细胞与骨质疏松症的关系研究进展 [J]. 中国骨质疏松杂志, 2015, 21(11): 1420-1424.
5 Weinerman S, Usera GL. Antiresorptive therapies for osteoporosis [J]. Oral Maxillofac Surg Clin North Am, 2015, 27(4): 555-560.
6 王会, 刘娟娟, 戚孟春, 等. 唑来膦酸对破骨细胞分化中CaMKⅡδ及下游基因表达的影响 [J]. 重庆医学, 2017, 46(10): 1308-1311.
7 Lagari VS, Mcaninch E, Baim S. Considerations regarding adherence of anti-osteoporosis therapy [J]. Postgrad Med, 2015, 127(1): 92-98.
8 Lange U, Schett G. Osteoporosis [J]. Z Rheumatol, 2016, 75(5): 442-443.
9 Hintze G, Graf D. [Osteoporosis] [J]. Med Monatsschr Pharm, 2016,39(6): 228-234.
10 邱贵兴. 老年骨质疏松性骨折的治疗策略 [J/CD]. 中华老年骨科与康复电子杂志, 2015, 1(1): 1-5.
11 Ishtiaq S, Fogelman I, Hampson G. Treatment of post-menopausal osteoporosis: beyond bisphosphonates [J]. J Endocrinol Invest, 2015, 38(1): 13-29.
12 Maraka S, Kennel KA. Bisphosphonates for the prevention and treatment of osteoporosis [J]. BMJ, 2015, 351(4): h3783.
13 Allen CS, Yeung JH, Vandermeer B, et al. Bisphosphonates for steroid-induced osteoporosis [J]. Cochrane Database Syst Rev, 2016, 10: 1347.
14 邢帅, 高延征, 高坤, 等. 双膦酸盐类药物治疗原发性骨质疏松症研究进展 [J]. 风湿病与关节炎, 2016, 5(3): 70-73.
15 Miller PD, Pannacciulli N, Brown JP, et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates [J]. J Clin Endocrinol Metab, 2016, 101(8): 3163.
16 Liu M, Guo L, Pei Y, et al. Efficacy of zoledronic acid in treatment of osteoporosis in men and women-a meta-analysis [J]. Int J Clin Exp Med, 2015, 8(3): 3855-3861.
17 Wang H, Hu ZH, Chen L, et al. [Influence of history of oral bisphosphonates on the incidence rate of fever after intravenous injection of zoledronic acid in patients with osteoporosis] [J]. Beijing da xue xue bao, 2016, 48(1): 680-682.
17 Yu T, Witten PE, Huysseune A, et al. Live imaging of osteoclast inhibition by bisphosphonates in a medaka osteoporosis model [J]. Dis Model Mech, 2016, 9(2): 155-163.
18 Hughes, DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo [J]. J Bone Miner Res, 1995, 10(10): 1478-1487.
19 Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) [J]. J Bone Miner Res, 2012, 27(2): 243-254.
20 Schilcher J, Koeppen V, Aspenberg P, et al. Risk of atypical femoral fracture during and after bisphosphonate use [J]. N Engl J Med, 2014, 371(10): 974-976.
21 Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation [J]. Nature, 2003, 423(6937): 337-342.
22 Kim JH, Kim N. Signaling pathways in osteoclast differentiation [J]. Chonnam Med J, 2016, 52(1): 12-17.
23 李子怡, 李玉坤. OPG/RANK/RANKL信号通路在骨质疏松症中的研究进展和应用 [J/CD]. 中华老年骨科与康复电子杂志, 2017, 3(2): 124-128.
24 Albert JS, Bhattacharyya N, Wolfe LA, et al. Impaired osteoblast and osteoclast function characterize the osteoporosis of Snyder-Robinson syndrome [J]. Orphanet J Rare Dis, 2015, 10(1): 27.

相似文献/References:

[1]赵志虎 李风波 马信龙 孙晓雷 马剑雄 张杨 王颖 卢斌 孙磊 王建宝 吕建伟.柚皮苷对共培养体系中成骨细胞活性及破骨细胞分化的影响[J].中华老年骨科与康复电子杂志,2015,(02):13.[doi:10.3877/cma.j.issn.2096-0263.2015.02.003]
　Zhao Zhihu,Li Fengbo,Ma Xinlong,et al.Effect of naringin on the activity of osteoblast and differentiation of osteoclast in a co-culture system[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2015,(01):13.[doi:10.3877/cma.j.issn.2096-0263.2015.02.003]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金项目（81572154），吴阶平医学基金会临床科研专项资助项目（320.6750.15185），天津市卫生局科技攻关项目（15KG123）
更新日期/Last Update: 2018-01-31